α-synuclein in the pathophysiology of Alzheimer’s disease

[1]  C. Tanner,et al.  Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. , 2019, Neurology.

[2]  A. Fagan,et al.  The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease , 2018, Acta Neuropathologica Communications.

[3]  Richard J. Caselli,et al.  Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease , 2018, Alzheimer's & dementia.

[4]  O. Isacson,et al.  Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age , 2018, Scientific Reports.

[5]  Ulf Dettmer.  Rationally Designed Variants of α-Synuclein Illuminate Its in vivo Structural Properties in Health and Disease , 2018, Front. Neurosci..

[6]  S. Gandhi,et al.  Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases , 2018, The FEBS journal.

[7]  J. Trojanowski,et al.  Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease , 2018, Alzheimer's & Dementia.

[8]  O. Sporns,et al.  Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers , 2018, Alzheimer's & Dementia.

[9]  G. Bloom,et al.  Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons , 2018, Acta Neuropathologica.

[10]  A. Tandon,et al.  Import and Export of Misfolded α-Synuclein , 2018, Front. Neurosci..

[11]  W. Klein,et al.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade , 2018, Journal of Alzheimer's disease : JAD.

[12]  J. Schott,et al.  Molecular biomarkers of Alzheimer's disease: progress and prospects , 2018, Disease Models & Mechanisms.

[13]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[14]  Nick C Fox,et al.  Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic , 2018, Alzheimer's Research & Therapy.

[15]  R. Riek,et al.  Cryo-EM structure of alpha-synuclein fibrils , 2018, bioRxiv.

[16]  Alan J. Thomas,et al.  Improving the identification of dementia with Lewy bodies in the context of an Alzheimer’s-type dementia , 2018, Alzheimer's Research & Therapy.

[17]  Romain F. Laine,et al.  C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction , 2018, Nature Communications.

[18]  D. Dickson,et al.  Multiple system atrophy and apolipoprotein E , 2018, Movement disorders : official journal of the Movement Disorder Society.

[19]  V. Lee,et al.  Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies , 2018, Neurobiology of Disease.

[20]  J. Trojanowski,et al.  A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. , 2018, Journal of Alzheimer's disease : JAD.

[21]  M. Ingelsson,et al.  Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes , 2017, The Journal of Neuroscience.

[22]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[23]  C. Wattmo,et al.  Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years , 2017, Alzheimer's Research & Therapy.

[24]  C. Jack,et al.  Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers , 2017, The Lancet Neurology.

[25]  K. Blennow.  A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood , 2017, Neurology and Therapy.

[26]  E. Masliah,et al.  Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology , 2017, Acta Neuropathologica Communications.

[27]  D. Bennett,et al.  Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits , 2017, Proceedings of the National Academy of Sciences.

[28]  P. Whitley,et al.  Steady-State Kinetics of α-Synuclein Ferrireductase Activity Identifies the Catalytically Competent Species. , 2017, Biochemistry.

[29]  K. Blennow,et al.  Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia , 2017, Alzheimer's & Dementia.

[30]  Giovanni B. Frisoni,et al.  Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment , 2017, Alzheimer's & Dementia.

[31]  R. Faull,et al.  α-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson’s disease patients , 2017, Scientific Reports.

[32]  K. Thorn,et al.  α-Synuclein Promotes Dilation of the Exocytotic Fusion Pore , 2017, Nature Neuroscience.

[33]  A. Nordberg,et al.  Tau PET imaging: present and future directions , 2017, Molecular Neurodegeneration.

[34]  P. Calabresi,et al.  Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease , 2017, Scientific Reports.

[35]  J. Olivo-Marin,et al.  Tunneling nanotubes spread fibrillar α‐synuclein by intercellular trafficking of lysosomes , 2016, The EMBO journal.

[36]  G. Bråthen,et al.  Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study , 2016, BMC Neurology.

[37]  E. Masliah,et al.  Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model , 2016, The Journal of Neuroscience.

[38]  G. Taglialatela,et al.  Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies. , 2016, Current pharmaceutical design.

[39]  M. Hasegawa,et al.  α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly* , 2016, The Journal of Biological Chemistry.

[40]  G. Bu,et al.  Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan , 2016, Molecular Neurodegeneration.

[41]  A. Björklund,et al.  Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain , 2016, Proceedings of the National Academy of Sciences.

[42]  N. Pervaiz,et al.  The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication , 2016, Scientific Reports.

[43]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[44]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[45]  Knockdown of α-synuclein in cerebral cortex improves neural behavior associated with apoptotic inhibition and neurotrophin expression in spinal cord transected rats , 2016, Apoptosis.

[46]  J. Trojanowski,et al.  Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology , 2016, Acta Neuropathologica.

[47]  Jun Wang,et al.  Rate of early onset Alzheimer's disease: a systematic review and meta-analysis. , 2015, Annals of translational medicine.

[48]  K. Blennow,et al.  Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study , 2015, Neurobiology of Aging.

[49]  Michel Goedert,et al.  Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein , 2015, Science.

[50]  D. Selkoe,et al.  KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity , 2015, Proceedings of the National Academy of Sciences.

[51]  Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation , 2015, Nature communications.

[52]  M. Carrillo,et al.  Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective , 2015, Alzheimer's & Dementia.

[53]  Karl Herrup,et al.  The case for rejecting the amyloid cascade hypothesis , 2015, Nature Neuroscience.

[54]  Kui Ye,et al.  Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders , 2015, International Psychogeriatrics.

[55]  Elisabeth L. Moussaud-Lamodière,et al.  Alpha-synuclein and tau: teammates in neurodegeneration? , 2014, Molecular Neurodegeneration.

[56]  P. McLean,et al.  α-Synuclein Multimers Cluster Synaptic Vesicles and Attenuate Recycling , 2014, Current Biology.

[57]  P. Deyn,et al.  Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels , 2014, Alzheimer's & Dementia.

[58]  T. Südhof,et al.  α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation , 2014, Proceedings of the National Academy of Sciences.

[59]  I. McKeith,et al.  The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis , 2014, Alzheimer's Research & Therapy.

[60]  D. Dickson,et al.  Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. , 2014, Brain : a journal of neurology.

[61]  K. Blennow,et al.  Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[62]  M. Gąssowska,et al.  Extracellular α-Synuclein Leads to Microtubule Destabilization via GSK-3β-Dependent Tau Phosphorylation in PC12 Cells , 2014, PloS one.

[63]  T. Golde,et al.  Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice , 2014, Acta Neuropathologica.

[64]  D. Aarsland,et al.  Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[65]  H. Berendse,et al.  Reduced α‐synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity , 2014, European journal of neurology.

[66]  E. Londos,et al.  Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. , 2014, Journal of Alzheimer's disease : JAD.

[67]  Michael Ewers,et al.  Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. , 2014, Journal of Alzheimer's disease : JAD.

[68]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[69]  E. Kapaki,et al.  The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer’s Disease , 2013, PLoS ONE.

[70]  B. Boeve,et al.  Incidence of dementia with Lewy bodies and Parkinson disease dementia. , 2013, JAMA neurology.

[71]  D. Selkoe,et al.  Defining the Native State of α-Synuclein , 2013, Neurodegenerative Diseases.

[72]  R. Edwards,et al.  The Function of α-Synuclein , 2013, Neuron.

[73]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[74]  F. Brodsky,et al.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds , 2013, Proceedings of the National Academy of Sciences.

[75]  D. Eliezer.  The mysterious C-terminal tail of alpha-synuclein: nanobody's guess. , 2013, Journal of molecular biology.

[76]  J. Trojanowski,et al.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease , 2013, Acta Neuropathologica.

[77]  M. Farrer,et al.  Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[78]  J. Weuve,et al.  Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.

[79]  Ronald Melki,et al.  G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome , 2013, Annals of neurology.

[80]  Douglas Galasko,et al.  Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems , 2013, Alzheimer's Research & Therapy.

[81]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[82]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[83]  Cornelia M. Wilson,et al.  Tau protein kinases: Involvement in Alzheimer's disease , 2013, Ageing Research Reviews.

[84]  D. Selkoe,et al.  In Vivo Cross-linking Reveals Principally Oligomeric Forms of α-Synuclein and β-Synuclein in Neurons and Non-neural Cells* , 2013, The Journal of Biological Chemistry.

[85]  Sandra E Black,et al.  Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.

[86]  L. Minthon,et al.  Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy , 2013, PloS one.

[87]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[88]  Min Shi,et al.  α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. , 2013, Journal of Alzheimer's disease : JAD.

[89]  E. Masliah,et al.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  Adam J. Trexler,et al.  Function and Dysfunction of α-Synuclein: Probing Conformational Changes and Aggregation by Single Molecule Fluorescence , 2012, Molecular Neurobiology.

[91]  R. Mayeux,et al.  Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[92]  D. Bennett,et al.  Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology , 2012, The Journal of Neuroscience.

[93]  Subhojit Roy,et al.  α-Synuclein Inhibits Intersynaptic Vesicle Mobility and Maintains Recycling-Pool Homeostasis , 2012, The Journal of Neuroscience.

[94]  R. Sakakibara,et al.  Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease , 2012, Alzheimer disease and associated disorders.

[95]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[96]  A. Björklund,et al.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons , 2012, Proceedings of the National Academy of Sciences.

[97]  E. Londos,et al.  Altered CSF orexin and α-synuclein levels in dementia patients. , 2012, Journal of Alzheimer's disease : JAD.

[98]  K. Tamura,et al.  Stimulatory effect of α‐synuclein on the tau‐phosphorylation by GSK‐3β , 2011, The FEBS journal.

[99]  A. McKee,et al.  Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[100]  Wei Wang,et al.  A soluble α-synuclein construct forms a dynamic tetramer , 2011, Proceedings of the National Academy of Sciences.

[101]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[102]  D. Selkoe,et al.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.

[103]  Portland Press Ltd.  The amyloid cascade hypothesis has misled the pharmaceutical industry. , 2011, Biochemical Society transactions.

[104]  E. Waxman,et al.  Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau , 2011, The Journal of Neuroscience.

[105]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[106]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[107]  D. Hong,et al.  The role of the C‐terminus of human α‐synuclein: Intra‐disulfide bonds between the C‐terminus and other regions stabilize non‐fibrillar monomeric isomers , 2011, FEBS letters.

[108]  P. Novick,et al.  Role of Rab GTPases in membrane traffic and cell physiology. , 2011, Physiological reviews.

[109]  O. Lindvall,et al.  Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. , 2011, Journal of Parkinson's disease.

[110]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[111]  S. Chandra,et al.  αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction , 2010, Proceedings of the National Academy of Sciences.

[112]  Jack H Freed,et al.  The Lipid-binding Domain of Wild Type and Mutant α-Synuclein , 2010, The Journal of Biological Chemistry.

[113]  Masaki Tanaka,et al.  Extracellular neurosin degrades α-synuclein in cultured cells , 2010, Neuroscience Research.

[114]  E. Masliah,et al.  A Pathologic Cascade Leading to Synaptic Dysfunction in α-Synuclein-Induced Neurodegeneration , 2010, The Journal of Neuroscience.

[115]  T. Tokuda,et al.  Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[116]  J. Trojanowski,et al.  Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline , 2010, The Journal of Neuroscience.

[117]  M. Ntzouni,et al.  Cell-Produced α-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival , 2010, The Journal of Neuroscience.

[118]  A. Manning-Boğ,et al.  Lysosomal Degradation of α-Synuclein in Vivo* , 2010, The Journal of Biological Chemistry.

[119]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[120]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[121]  W. M. van der Flier,et al.  CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[122]  J. Trojanowski,et al.  Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.

[123]  L. Stefanis,et al.  Functional dissection of the α‐synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219 , 2009, Journal of neurochemistry.

[124]  T. Duka,et al.  α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[125]  Y. Stern,et al.  Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. , 2009, Archives of neurology.

[126]  F. Schmitt,et al.  Lewy Body Pathology in Normal Elderly Subjects , 2009, Journal of neuropathology and experimental neurology.

[127]  Torsten Schwede,et al.  Automated comparative protein structure modeling with SWISS‐MODEL and Swiss‐PdbViewer: A historical perspective , 2009, Electrophoresis.

[128]  Marie-Claude Potier,et al.  Classification and basic pathology of Alzheimer disease , 2009, Acta Neuropathologica.

[129]  E. Lemke,et al.  Interplay of α-synuclein binding and conformational switching probed by single-molecule fluorescence , 2009, Proceedings of the National Academy of Sciences.

[130]  Adam J. Trexler,et al.  Alpha-synuclein binds large unilamellar vesicles as an extended helix. , 2009, Biochemistry.

[131]  K. Blennow,et al.  Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? , 2009, Neuroscience Letters.

[132]  R. Melis,et al.  Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. , 2009, Journal of Alzheimer's disease : JAD.

[133]  Seung-Jae Lee,et al.  Controlling the mass action of α‐synuclein in Parkinson’s disease , 2008, Journal of neurochemistry.

[134]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[135]  E. Masliah,et al.  Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases , 2008, PloS one.

[136]  A. Eklund,et al.  GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein , 2008, Proceedings of the National Academy of Sciences.

[137]  Yoshihisa Watanabe,et al.  Cleavage of normal and pathological forms of α-synuclein by neurosin in vitro , 2008, Neuroscience Letters.

[138]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[139]  T. Dawson.  Faculty Opinions recommendation of A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. , 2008 .

[140]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[141]  T. Südhof,et al.  A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides , 2008, Nature Neuroscience.

[142]  A. Kakita,et al.  Enhanced Accumulation of Phosphorylated α-Synuclein and Elevated β-Amyloid 42/40 Ratio Caused by Expression of the Presenilin-1 ΔT440 Mutant Associated with Familial Lewy Body Disease and Variant Alzheimer's Disease , 2007, The Journal of Neuroscience.

[143]  Joseph E LeDoux.  The amygdala , 2007, Current Biology.

[144]  I. Bertini,et al.  Paramagnetism-based NMR restraints provide maximum allowed probabilities for the different conformations of partially independent protein domains. , 2007, Journal of the American Chemical Society.

[145]  A. Kakita,et al.  Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[146]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[147]  K. Sode,et al.  Effect of Reparation of Repeat Sequences in the Human α-Synuclein on Fibrillation Ability , 2006, International journal of biological sciences.

[148]  J. Pettegrew,et al.  Interaction between Aβ Peptide and α Synuclein: Molecular Mechanisms in Overlapping Pathology of Alzheimer’s and Parkinson’s in Dementia with Lewy Body Disease , 2006, Neurochemical Research.

[149]  Dennis W. Dickson,et al.  Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of &agr;-Synucleinopathy , 2006, Journal of neuropathology and experimental neurology.

[150]  G. Schellenberg,et al.  Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. , 2006, Archives of neurology.

[151]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[152]  T. Duka,et al.  Highly Potent and Specific GSK‐3β Inhibitors That Block Tau Phosphorylation and Decrease α‐Synuclein Protein Expression in a Cellular Model of Parkinson's Disease , 2006, ChemMedChem.

[153]  T. Tokuda,et al.  Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.

[154]  J. Pettegrew,et al.  Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. , 2006, Neurochemical research.

[155]  J. Morris,et al.  Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. , 2005, Archives of neurology.

[156]  Thomas C. Südhof,et al.  α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.

[157]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[158]  C. Griesinger,et al.  Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[159]  S. Resnick,et al.  Alpha-Synuclein Lesions in Normal Aging, Parkinson Disease, and Alzheimer Disease: Evidence from the Baltimore Longitudinal Study of Aging (BLSA) , 2005, Journal of neuropathology and experimental neurology.

[160]  C. Dobson,et al.  Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[161]  T. Südhof,et al.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.

[162]  R. Hawkins,et al.  α‐Synuclein produces a long‐lasting increase in neurotransmitter release , 2004, The EMBO journal.

[163]  Giuseppe Battaglia,et al.  Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[164]  J. Goudreau,et al.  Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. , 2004, Neurotoxicology.

[165]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[166]  E. Iseki.  Dementia with Lewy bodies: Reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease , 2004, Neuropathology : official journal of the Japanese Society of Neuropathology.

[167]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[168]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[169]  A. Davies,et al.  Neurons Expressing the Highest Levels of γ-Synuclein Are Unaffected by Targeted Inactivation of the Gene , 2003, Molecular and Cellular Biology.

[170]  Jie Li,et al.  The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.

[171]  H. Erdjument-Bromage,et al.  Parkinson's Disease-associated α-Synuclein Is a Calmodulin Substrate* , 2003, The Journal of Biological Chemistry.

[172]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[173]  P. Lansbury,et al.  The N-Terminal Repeat Domain of α-Synuclein Inhibits β-Sheet and Amyloid Fibril Formation† , 2003 .

[174]  H. Erdjument-Bromage,et al.  Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. , 2003, The Journal of biological chemistry.

[175]  P. Lansbury,et al.  The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. , 2003, Biochemistry.

[176]  Chul-hak Yang,et al.  Structural and Functional Implications of C-Terminal Regions of α-Synuclein† , 2002 .

[177]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[178]  Hong-Yu Hu,et al.  Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation. , 2002, Biopolymers.

[179]  Chul-hak Yang,et al.  Structural and functional implications of C-terminal regions of alpha-synuclein. , 2002, Biochemistry.

[180]  J. George,et al.  The synucleins , 2001, Genome Biology.

[181]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[182]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[183]  G. Asano,et al.  α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation , 2001, Brain Research.

[184]  L. Mucke,et al.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[185]  T. Bayer,et al.  Lewy body variant of Alzheimer's disease: α‐synuclein in dystrophic neurites of Aβ plaques , 2000 .

[186]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[187]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[188]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[189]  K. Kosaka,et al.  Occurrence of human α-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease , 2000, Journal of the Neurological Sciences.

[190]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[191]  K. Kosaka,et al.  Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease. , 2000, Journal of the neurological sciences.

[192]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[193]  T. Bayer,et al.  Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques. , 2000, Neuroreport.

[194]  Michael Davis,et al.  The amygdala , 2000, Current Biology.

[195]  R. Schulz,et al.  Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. , 1999, JAMA.

[196]  J. Trojanowski,et al.  Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease , 1999, Annals of neurology.

[197]  J Q Trojanowski,et al.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.

[198]  L. Thal,et al.  Cognitive decline is faster in Lewy body variant than in Alzheimer's disease , 1998, Neurology.

[199]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[200]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[201]  U. Igbavboa,et al.  Lipid Binding to Amyloid β‐Peptide Aggregates: Preferential Binding of Cholesterol as Compared with Phosphatidylcholine and Fatty Acids , 1997, Journal of neurochemistry.

[202]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[203]  D. Wilson,et al.  Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. , 1997, The American journal of pathology.

[204]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[205]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[206]  D. Salmon,et al.  The synaptic protein NACP is abnormally expressed during the progression of Alzheimer' s disease , 1996, Brain Research.

[207]  K. Imahori,et al.  Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[208]  K. Imahori,et al.  Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β , 1996, Neuroscience Letters.

[209]  E. Masliah,et al.  Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. , 1996, The American journal of pathology.

[210]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[211]  S. Lovestone,et al.  Stimulation of MAP kinase by v‐raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau , 1995, FEBS letters.

[212]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[213]  D. Galasko,et al.  Apolipoprotein-E ε-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease , 1994, Neuroscience Letters.

[214]  S. Shioda,et al.  Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization. , 1994, Brain research. Molecular brain research.

[215]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[216]  E. Masliah,et al.  Plaque‐Only Alzheimer Disease is Usually the Lewy Body Variant, and Vice Versa , 1993, Journal of neuropathology and experimental neurology.

[217]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[218]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[219]  R. Scheller,et al.  The rat brain synucleins; family of proteins transiently associated with neuronal membrane. , 1991, Brain research. Molecular brain research.

[220]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[221]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[222]  L. Thal,et al.  The Lewy body variant of Alzheimer's disease , 1990, Neurology.

[223]  C. Bergeron,et al.  Lewy Bodies in Alzheimer Disease‐One or Two Diseases? , 1989, Alzheimer disease and associated disorders.

[224]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[225]  R. Brady,et al.  THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE. , 1965, The Journal of biological chemistry.